Modicus Prime announced it raised a total of $8 million in funding following an additional $4.5 million investment led by Frist Cressey Ventures, with participation from Silverton Partners and Oncology Ventures.
The company said the financing follows deployments of its Trustworthy AI Compliance Software across pharmaceutical companies, contract research organizations, contract manufacturing organizations, and other regulated healthcare sectors.
Modicus Prime develops compliance infrastructure software designed to help pharmaceutical organizations deploy and manage AI systems within regulated GxP environments. The platform integrates with pharmaceutical technology stacks and quality management systems to provide centralized oversight for AI governance and regulatory compliance across global operations.
According to the company, the platform serves as a single source of truth for compliance with regulators, including the FDA and European Medicines Agency, throughout the AI lifecycle. Modicus Prime said the software is designed to reduce operational friction between data science, IT, quality assurance, and compliance teams while enabling scalable AI adoption across regulated environments.
The company said compliant AI deployment can help pharmaceutical organizations reduce compliance risks, protect returns on AI investments, and avoid costly quality control failures that the industry estimates at approximately $50 billion annually.
Modicus Prime CEO Taylor Chartier co-authored the ISPE GAMP AI Guide and BioPhorum AI Implementation publication in 2025 and helped lead educational initiatives focused on implementing AI and machine learning technologies within regulated pharmaceutical environments.
The company said the new funding will support continued enhancement of its platform and expansion of customer support capabilities for global pharmaceutical customers deploying AI technologies at scale.
Modicus Prime was previously a resident at Johnson & Johnson Innovation’s JLABS programs in Texas Medical Center and South San Francisco.
KEY QUOTES:
“At the end of the day, every advancement in this industry must serve the patient. By simplifying and strengthening AI compliance, Modicus Prime enables pharmaceutical leaders to stay focused on accelerating innovation and delivering life-saving therapies to those who need them most.”
Senator Bill Frist, MD, Founding Partner, Frist Cressey Ventures
“Pharmaceutical companies are investing heavily in AI, but without the infrastructure to deploy it compliantly and measure ROI, that investment is at risk. Adjacent healthcare sectors, including payers and providers, express the same need for compliance infrastructure. This is the gap our Trustworthy AI Compliance Software addresses, enabling scalable AI adoption across regulated environments.”
Taylor Chartier, CEO, Modicus Prime
“The next wave of cancer breakthroughs are coming, and every manufacturer has to survive a regulatory audit to ensure those drugs get to patients who need them. Modicus Prime is the compliance layer that makes this happen.”
Ben Freeberg, Oncology Ventures
